Background
Phase II randomized trial. 306 patients with locally advanced rectal cancer (cT3–4 or cN+, distal two-thirds of rectum). Tested whether consolidation TNT sequence (CRT first, then chemotherapy) achieves higher pCR than induction TNT (chemotherapy first, then CRT). Both arms proceeded to TME surgery thereafter.
Interventions and follow up
Arm A (Induction TNT): CAPOX × 3 cycles, then CRT (50.4 Gy + capecitabine), then TME
Arm B (Consolidation TNT): CRT first (50.4 Gy + capecitabine), then CAPOX × 3 cycles, then TME
Primary endpoint: Pathological complete response (pCR, ypT0N0)
Median follow-up: 43 months
Arm B (Consolidation TNT): CRT first (50.4 Gy + capecitabine), then CAPOX × 3 cycles, then TME
Primary endpoint: Pathological complete response (pCR, ypT0N0)
Median follow-up: 43 months
Results
pCR: 17% (induction) vs 25% (consolidation), OR 1.68 (95% CI 1.01–2.81), P=.046
3-yr DFS: 73% vs 75%, HR 0.87, P=.53
3-yr OS: 90% vs 91%, P=.69
R0 resection: 96% vs 97%
Organ preservation (NOM or local excision): 12% vs 21%
3-yr DFS: 73% vs 75%, HR 0.87, P=.53
3-yr OS: 90% vs 91%, P=.69
R0 resection: 96% vs 97%
Organ preservation (NOM or local excision): 12% vs 21%
Adverse events
Overall grade ≥3: 32% (induction) vs 27% (consolidation), P=.43
Most common: diarrhea, hand-foot syndrome, peripheral neuropathy; comparable between arms
Surgical delay: 7% (induction) vs 10% (consolidation)
Most common: diarrhea, hand-foot syndrome, peripheral neuropathy; comparable between arms
Surgical delay: 7% (induction) vs 10% (consolidation)
Conclusions
Consolidation TNT (CRT → chemotherapy) produced significantly higher pCR than induction TNT (25% vs 17%, P=.046) with numerically higher rates of organ preservation (21% vs 12%). DFS and OS were similar between arms at 3 years.
Key Limitations
Phase II trial, underpowered for DFS and OS comparison. Only 3 cycles of CAPOX used — less intensive than FOLFIRINOX in PRODIGE-23 or full CAPOX in RAPIDO/STELLAR. Organ preservation was not a formal primary endpoint. Short follow-up insufficient to assess long-term DFS/OS impact of the pCR difference.
Clinical Context
CAO/ARO/AIO-12 was pivotal in establishing consolidation TNT (CRT first, then chemotherapy) as the preferred sequence over induction TNT, a finding reflected in ESMO guidance. The superior pCR with consolidation sequence was further supported by OPRA: consolidation FOLFOX or CAPOX after CRT is a standard TNT approach for high-risk LARC when organ preservation is a goal.
References